|
|
|
Insider
Information: |
Akkaraju Srinivas |
Relationship: |
|
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
19 |
|
Direct
Shares |
3,981,393 |
|
Indirect Shares
|
37,764,445 |
|
|
Direct
Value |
$19,869,019 |
|
|
Indirect Value
|
$418,961,621 |
|
|
Total
Shares |
41,745,838 |
|
|
Total
Value |
$438,830,640 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
2
|
2
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
2
|
2
|
|
|
|
Gain/Loss Ratio : |
-2.0
|
-2.0
|
Percentage
Gain/Loss : |
-38.8%
|
-88.4%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Pharmos Corp |
PARS |
Director |
|
0 |
2006-10-25 |
2,845,160 |
Premium* |
|
Seagen Inc |
SGEN |
Director |
2020-05-15 |
41,503 |
2008-09-22 |
600,559 |
Premium* |
|
Paratek Pharmaceuticals Inc |
PRTK |
Former 10% Beneficial ... |
2011-07-19 |
1,181,967 |
|
0 |
Premium* |
|
World Heart Corp |
WHRT |
10% Owner |
2012-08-02 |
0 |
2010-01-26 |
0 |
Premium* |
|
Icagen Inc |
ICGN |
|
2011-07-28 |
200,500 |
|
0 |
Premium* |
|
Synageva BioPharma Corp |
GEVA |
Former Director |
|
0 |
2012-06-27 |
1,026,832 |
Premium* |
|
Durata Therapeutics, Inc. |
DRTX |
10% Owner |
2012-07-24 |
0 |
2012-07-24 |
3,028,439 |
Premium* |
|
MEI Pharma Inc |
MEIP |
10% Owner |
2013-02-19 |
2,502,775 |
|
0 |
Premium* |
|
Zs Pharma, Inc. |
ZSPH |
Director |
2015-12-17 |
0 |
2014-06-23 |
609,455 |
Premium* |
|
aTyr Pharma Inc |
LIFE |
Former 10% Owner, Dire... |
2015-05-12 |
0 |
2015-05-12 |
1,866,126 |
Premium* |
|
Aravive Inc |
ARAV |
Director |
2019-12-02 |
31,815 |
2019-12-02 |
576,066 |
Premium* |
|
Syros Pharmaceuticals, Inc. |
SYRS |
|
2024-09-16 |
9,333 |
2023-12-21 |
1,786,427 |
Premium* |
|
Principia Biopharma Inc |
PRNB |
Director |
2018-09-18 |
0 |
2018-09-18 |
383,480 |
Premium* |
|
Chinook Therapeutics Inc |
KDNY |
Director |
2023-08-11 |
0 |
2023-08-11 |
0 |
Premium* |
|
Lenz Therapeutics |
LENZ |
10% Owner |
2021-06-29 |
0 |
2022-04-12 |
8,497,067 |
Premium* |
|
Scholar Rock Holding Corp |
SRRK |
|
2024-06-27 |
13,500 |
2024-06-27 |
6,788,609 |
Premium* |
|
Cargo Therapeutics, Inc. |
CRGX |
10% Owner |
|
0 |
2024-05-30 |
4,415,689 |
Premium* |
|
Mineralys Therapeutics, Inc. |
MLYS |
|
2024-02-12 |
0 |
2024-02-12 |
5,074,916 |
Premium* |
|
Vtv Therapeutics Inc. |
VTVT |
|
2024-02-27 |
0 |
2024-02-27 |
265,620 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
127 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 4 of 6
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
SGEN |
Seagen Inc |
Director |
|
2020-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,335 |
41,503 |
0 |
- |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2020-06-23 |
4 |
AS |
$11.11 |
$565,930 |
I/I |
(50,953) |
1,542,317 |
0 |
- |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2020-06-24 |
4 |
AS |
$11.07 |
$539,788 |
I/I |
(48,775) |
1,493,542 |
0 |
- |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2020-06-25 |
4 |
AS |
$11.15 |
$612,850 |
I/I |
(54,972) |
1,438,570 |
0 |
- |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2020-07-01 |
4 |
AS |
$11.01 |
$50,966 |
I/I |
(4,627) |
1,433,943 |
0 |
- |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2020-08-17 |
4 |
AS |
$13.00 |
$9,672 |
I/I |
(744) |
1,433,199 |
0 |
- |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2020-08-18 |
4 |
AS |
$13.10 |
$2,076,724 |
I/I |
(158,583) |
1,274,616 |
0 |
- |
|
KDNY |
Chinook Therapeutics Inc |
Director |
|
2020-10-05 |
4 |
A |
$0.00 |
$0 |
I/I |
3,168,388 |
3,168,388 |
0 |
- |
|
SYRS |
Syros Pharmaceuticals, In... |
Director |
|
2020-12-08 |
4 |
A |
$0.00 |
$0 |
I/I |
625,000 |
1,899,616 |
0 |
- |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2021-06-29 |
4 |
B |
$17.00 |
$8,500,000 |
I/I |
500,000 |
37,753 |
1.5 |
- |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2021-06-29 |
4 |
A |
$0.00 |
$0 |
I/I |
6,931,623 |
22,753 |
0 |
- |
|
KDNY |
Chinook Therapeutics Inc |
Director |
|
2021-08-18 |
4 |
B |
$11.98 |
$2,497,830 |
I/I |
208,500 |
3,376,888 |
2.1 |
- |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2021-10-06 |
4 |
B |
$13.83 |
$850,199 |
I/I |
61,475 |
7,455,345 |
1.5 |
- |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2021-10-07 |
4 |
B |
$14.94 |
$134,774 |
I/I |
9,021 |
7,464,366 |
1.5 |
- |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2021-10-08 |
4 |
B |
$13.12 |
$984,000 |
I/I |
75,000 |
7,539,366 |
1.5 |
- |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2021-10-13 |
4 |
B |
$13.22 |
$600,188 |
I/I |
45,400 |
7,584,766 |
1.5 |
- |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2021-10-14 |
4 |
B |
$12.50 |
$38,750 |
I/I |
3,100 |
7,587,866 |
1.5 |
- |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2021-10-15 |
4 |
B |
$12.49 |
$28,727 |
I/I |
2,300 |
7,590,166 |
1.5 |
- |
|
KDNY |
Chinook Therapeutics Inc |
Director |
|
2021-11-15 |
4 |
B |
$14.00 |
$17,010,000 |
I/I |
1,215,000 |
4,591,888 |
2.1 |
- |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2021-12-15 |
4 |
B |
$10.19 |
$227,533 |
I/I |
22,329 |
7,814,180 |
1.5 |
- |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2022-01-19 |
4 |
B |
$9.24 |
$504,181 |
I/I |
54,565 |
7,868,745 |
1.5 |
- |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2022-01-20 |
4 |
B |
$8.92 |
$384,497 |
I/I |
43,105 |
7,911,850 |
1.5 |
- |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2022-01-21 |
4 |
B |
$8.99 |
$899,000 |
I/I |
100,000 |
8,011,850 |
1.5 |
- |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2022-01-24 |
4 |
B |
$8.70 |
$200,100 |
I/I |
23,000 |
8,034,850 |
1.5 |
- |
|
LENZ |
Lenz Therapeutics |
10% Owner |
|
2022-04-11 |
4 |
B |
$4.07 |
$303,068 |
I/I |
74,464 |
8,109,314 |
1.5 |
- |
|
127 Records found
|
|
Page 4 of 6 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|